- FDA Says First Round of Tests Show No Live Virus in Pasteurized Milk
- King Charles Returns to Duties After Cancer Treatment
- Biden Administration Delays Menthol Cigarette Ban
- Blood Test Might Predict Knee Osteoarthritis Years Early
- Dogs Can Get Lyme Disease, Too
- Spinal Cord Injury Damages Metabolism, and Scientists Now Know Why
- Syphilis Is Increasingly Displaying Atypical, Severe Symptoms
- Climate Change Could Be Good News for Viruses Like COVID
- Vaccines Have Saved 154 Million Lives, Mostly Babies, Over Past 50 Years
- Scientists Discover Cause of Rare Movement Disorder
Alecensa Approved for Lung Cancer Tied to Gene Mutation
Alecensa (alectinib) has been approved by the U.S. Food and Drug administration to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer, the agency said Friday in a news release. This type of cancer often spreads to the brain.
The pill is sanctioned for instances of worsening disease after patients take a standard therapy called Xalkori (crizotinib), or if they are unable to tolerate Xalkori.
More than 221,000 people in the United States are projected to develop lung cancer this year, and more than 158,000 will die from it, according to the National Cancer Institute. ALK gene mutations are involved in about 5 percent of cases of non-small cell lung cancer, the FDA said.
Alecensa is designed to block the effects of the ALK protein, thereby preventing these cancer cells from growing and spreading.
The most common side effects of the drug are fatigue, constipation, swelling and muscle pain. More serious side effects could include liver problems, life-threatening lung inflammation, slowed heartbeat and severe muscle problems. Users also may be prone to more easily becoming sunburned.
Alecensa is marketed by San Francisco-based Genentec.
More information
Learn more from the FDA.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.